CN115251270A - 一种富含心脑血管健康因子的固体饮料及其制作方法 - Google Patents
一种富含心脑血管健康因子的固体饮料及其制作方法 Download PDFInfo
- Publication number
- CN115251270A CN115251270A CN202210919042.XA CN202210919042A CN115251270A CN 115251270 A CN115251270 A CN 115251270A CN 202210919042 A CN202210919042 A CN 202210919042A CN 115251270 A CN115251270 A CN 115251270A
- Authority
- CN
- China
- Prior art keywords
- powder
- cardiovascular
- solid beverage
- instant
- rich
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 55
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 46
- 239000007787 solid Substances 0.000 title claims abstract description 43
- 230000036541 health Effects 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 239000000843 powder Substances 0.000 claims abstract description 91
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 24
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 21
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 20
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 18
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims abstract description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 11
- 235000013311 vegetables Nutrition 0.000 claims abstract description 11
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 10
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 10
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 10
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims abstract description 10
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims abstract description 10
- 229960000304 folic acid Drugs 0.000 claims abstract description 10
- 235000019152 folic acid Nutrition 0.000 claims abstract description 10
- 239000011724 folic acid Substances 0.000 claims abstract description 10
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 10
- 229940013618 stevioside Drugs 0.000 claims abstract description 10
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims abstract description 10
- 235000019202 steviosides Nutrition 0.000 claims abstract description 10
- RBCOYOYDYNXAFA-UHFFFAOYSA-L (5-hydroxy-4,6-dimethylpyridin-3-yl)methyl phosphate Chemical compound CC1=NC=C(COP([O-])([O-])=O)C(C)=C1O RBCOYOYDYNXAFA-UHFFFAOYSA-L 0.000 claims abstract description 9
- 239000004475 Arginine Substances 0.000 claims abstract description 9
- 244000269722 Thea sinensis Species 0.000 claims abstract description 9
- 229930003316 Vitamin D Natural products 0.000 claims abstract description 9
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 9
- 244000273928 Zingiber officinale Species 0.000 claims abstract description 9
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 9
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000008397 ginger Nutrition 0.000 claims abstract description 9
- 229960003080 taurine Drugs 0.000 claims abstract description 9
- 235000019166 vitamin D Nutrition 0.000 claims abstract description 9
- 239000011710 vitamin D Substances 0.000 claims abstract description 9
- 150000003710 vitamin D derivatives Chemical class 0.000 claims abstract description 9
- 229940046008 vitamin d Drugs 0.000 claims abstract description 9
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000001103 potassium chloride Substances 0.000 claims abstract description 8
- 235000011164 potassium chloride Nutrition 0.000 claims abstract description 8
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 8
- 235000020183 skimmed milk Nutrition 0.000 claims abstract description 8
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims abstract description 7
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 7
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims abstract description 7
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims abstract description 7
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 7
- 239000000230 xanthan gum Substances 0.000 claims abstract description 7
- 229940082509 xanthan gum Drugs 0.000 claims abstract description 7
- 229920001285 xanthan gum Polymers 0.000 claims abstract description 7
- 235000010493 xanthan gum Nutrition 0.000 claims abstract description 7
- 235000001968 nicotinic acid Nutrition 0.000 claims abstract description 4
- 239000011664 nicotinic acid Substances 0.000 claims abstract description 4
- 229960003512 nicotinic acid Drugs 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 16
- 235000018102 proteins Nutrition 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 11
- 230000001954 sterilising effect Effects 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 235000003599 food sweetener Nutrition 0.000 claims description 8
- 239000003765 sweetening agent Substances 0.000 claims description 8
- 241000208688 Eucommia Species 0.000 claims description 7
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 6
- 244000105624 Arachis hypogaea Species 0.000 claims description 6
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 6
- 235000018262 Arachis monticola Nutrition 0.000 claims description 6
- 244000088415 Raphanus sativus Species 0.000 claims description 6
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 6
- 238000007908 dry granulation Methods 0.000 claims description 6
- 239000008157 edible vegetable oil Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 235000020232 peanut Nutrition 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 235000010356 sorbitol Nutrition 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 240000007124 Brassica oleracea Species 0.000 claims description 4
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 4
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 4
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 4
- 240000000249 Morus alba Species 0.000 claims description 4
- 235000008708 Morus alba Nutrition 0.000 claims description 4
- 235000020379 cucumber juice Nutrition 0.000 claims description 4
- 235000015193 tomato juice Nutrition 0.000 claims description 4
- 238000005550 wet granulation Methods 0.000 claims description 4
- 240000001592 Amaranthus caudatus Species 0.000 claims description 3
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims description 3
- 244000067456 Chrysanthemum coronarium Species 0.000 claims description 3
- 235000007871 Chrysanthemum coronarium Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical group OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 108010073771 Soybean Proteins Proteins 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- 239000004178 amaranth Substances 0.000 claims description 3
- 235000012735 amaranth Nutrition 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000007516 Chrysanthemum Nutrition 0.000 claims 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 13
- 235000010215 titanium dioxide Nutrition 0.000 abstract description 6
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 238000009098 adjuvant therapy Methods 0.000 abstract description 3
- 238000013461 design Methods 0.000 abstract description 3
- 239000000945 filler Substances 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 abstract 1
- 229960004106 citric acid Drugs 0.000 abstract 1
- 235000015165 citric acid Nutrition 0.000 abstract 1
- 229960002816 potassium chloride Drugs 0.000 abstract 1
- 229960005196 titanium dioxide Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 21
- 239000008280 blood Substances 0.000 description 21
- 235000013616 tea Nutrition 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000003405 preventing effect Effects 0.000 description 7
- 206010020772 Hypertension Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- -1 32 mg of nikkin Chemical compound 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000019622 heart disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 102100034983 E3 ubiquitin-protein ligase ZNRF4 Human genes 0.000 description 2
- 101000802410 Homo sapiens E3 ubiquitin-protein ligase ZNRF4 Proteins 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- ARPUHYJMCVWYCZ-UHFFFAOYSA-N ciprofloxacin hydrochloride hydrate Chemical compound O.Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 ARPUHYJMCVWYCZ-UHFFFAOYSA-N 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 235000019007 dietary guidelines Nutrition 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HUJXHFRXWWGYQH-UHFFFAOYSA-O sinapine Chemical compound COC1=CC(\C=C\C(=O)OCC[N+](C)(C)C)=CC(OC)=C1O HUJXHFRXWWGYQH-UHFFFAOYSA-O 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 210000003556 vascular endothelial cell Anatomy 0.000 description 2
- ZJSJQWDXAYNLNS-UHFFFAOYSA-N (+) pinoresinol-4,4'-di-O-beta-D-glucopyranoside Natural products COC1=CC(C2C3C(C(OC3)C=3C=C(OC)C(OC4C(C(O)C(O)C(CO)O4)O)=CC=3)CO2)=CC=C1OC1OC(CO)C(O)C(O)C1O ZJSJQWDXAYNLNS-UHFFFAOYSA-N 0.000 description 1
- FFDULTAFAQRACT-NYYYOYJKSA-N (-)-syringaresinol O,O'-bis(beta-D-glucoside) Chemical compound COC1=CC([C@H]2[C@H]3[C@H]([C@@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=C(OC)C=3)CO2)=CC(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FFDULTAFAQRACT-NYYYOYJKSA-N 0.000 description 1
- ZJSJQWDXAYNLNS-FUPWJLLWSA-N (2s,3r,4s,5s,6r)-2-[4-[(3s,3ar,6s,6ar)-6-[3-methoxy-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-2-methoxyphenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound COC1=CC([C@@H]2[C@@H]3[C@@H]([C@H](OC3)C=3C=C(OC)C(O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)=CC=3)CO2)=CC=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZJSJQWDXAYNLNS-FUPWJLLWSA-N 0.000 description 1
- IYGAMTQMILRCCI-UHFFFAOYSA-N 3-aminopropane-1-thiol Chemical compound NCCCS IYGAMTQMILRCCI-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-UHFFFAOYSA-N D-Erythrose Natural products OCC(O)C(O)C=O YTBSYETUWUMLBZ-UHFFFAOYSA-N 0.000 description 1
- YTBSYETUWUMLBZ-IUYQGCFVSA-N D-erythrose Chemical compound OC[C@@H](O)[C@@H](O)C=O YTBSYETUWUMLBZ-IUYQGCFVSA-N 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 206010056474 Erythrosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000010496 Heart Arrest Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000008167 Magnesium Deficiency Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 208000007642 Vitamin B Deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 230000007488 abnormal function Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- NLDDIKRKFXEWBK-AWEZNQCLSA-N gingerol Chemical compound CCCCC[C@H](O)CC(=O)CCC1=CC=C(O)C(OC)=C1 NLDDIKRKFXEWBK-AWEZNQCLSA-N 0.000 description 1
- JZLXEKNVCWMYHI-UHFFFAOYSA-N gingerol Natural products CCCCC(O)CC(=O)CCC1=CC=C(O)C(OC)=C1 JZLXEKNVCWMYHI-UHFFFAOYSA-N 0.000 description 1
- 235000002780 gingerol Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 244000237330 gutta percha tree Species 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 235000020344 instant tea Nutrition 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- USOSNFWVEWONDB-UHFFFAOYSA-N liriodendrin Natural products COc1cc(cc(OC)c1OC2OC(CO)C(O)C(O)C2O)C3OC(C)(C)C4C(OC(C)(C)C34)c5cc(OC)c(OC6OC(CO)C(O)C(O)C6O)c(OC)c5 USOSNFWVEWONDB-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000004764 magnesium deficiency Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002885 thrombogenetic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/723—Xanthans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
本发明具体公开了一种富含心脑血管健康因子的固体饮料及其制作方法,所述饮料包括如下配方原料:填充料、脱脂乳粉、低聚肽、精氨酸、速溶蔬菜粉、速溶杜仲叶汁粉、二氧化硅、茶多酚、速溶姜粉、甜菊甙、氯化钾、黄原胶、柠檬酸、羧甲基纤维素、牛磺酸、二氧化钛、尼克素、维生素B6、叶酸、维生素B12、维生素D。本发明饮料配方设计合理安全,各组分间相互协同作用,可以有效预防和辅助治疗心脑血管疾病的发生,且该产品安全、有效性高、无毒副作用,是一种优质的预防和辅助治疗心脑血管疾病的日常饮料;同时制备方法简单,适合规模化工业化生产。
Description
技术领域
本发明属于重组固体饮料加工技术领域,尤其涉及一种富含心脑血管健康因子的固体饮料及其制作方法。
背景技术
心脑血管疾病(或三高症)主要由不当饮食导致,其发展自儿童时期就会开始。我国有2亿超重或者肥胖者、2.7亿高血压患者、1.6亿血脂异常者(包括1亿高血脂者);此外,我国有近一半人血糖异常(增加糖尿病风险或部分已患糖尿病,同时危害心脑血管健康)。因此,从儿童时代起,坚持健康饮食对于降低上述这些病患的风险是必不可少的。
我国膳食指南建议每位成年男性每天喝1700ml水,每位成年女性每天喝1500ml水,所以每天补充饮料对维持人体健康非常重要。同时,膳食指南还建议少喝或不喝含蔗糖、葡萄糖等能提供能量的饮料。除此而外,蔗糖还能导致龋齿。纵观我国现实的饮料市场,大多数饮料中都含有蔗糖或果葡糖浆,这一饮料市场现状应该有所改变才符合健康要求。
另一个重要的方面,缺乏一些营养素会增加人体患心脑血管疾病风险或导致血脂/血糖异常的风险。也就是说,在每日的饮食中始终应该确保有适量的这些营养素的摄入。
还有一个重要的方面,适当地摄入有些食品级生物活性物具有降低血脂/血糖异常风险的作用。因此,在日常饮食中补充这些生物活性物,对于人体心脑血管健康而言也有重要意义。
通过富含心脑血管健康因子的饮料以尽可能地消除膳食危险因素,应该是维持心脑血管健康首先需要考虑的。目前市场上缺少富含心脑血管健康因子的低能量复合饮料,本发明提供一种富含心脑血管健康因子的固体饮料及其制作方法,以填补市场在这方面的空白。
发明内容
本发明的目的在于一种富含心脑血管健康因子的固体饮料及其制作方法,该饮料配方设计合理巧妙,各组分间相互协同,最大程度地发挥对心脑血管疾病的预防和辅助治疗作用,且该饮料安全、有效、无毒副作用。
为了达到上述目的,本发明的技术方案为:
一种富含心脑血管健康因子的固体饮料,所述饮料包括如下配方原料:填充料40-70克、脱脂乳粉2-10克、低聚肽1-5克、精氨酸0.5-2克、速溶蔬菜粉0.5-4克、速溶杜仲叶汁粉0.5-4克、二氧化硅0.5-3克、茶多酚0.5-2克、速溶姜粉0.5-2克、甜菊甙0.1-0.2克、氯化钾1-2克、黄原胶0-1克、柠檬酸0-0.7克、羧甲基纤维素0-0.5克、牛磺酸0-0.2克、二氧化钛0-0.05克、尼克素32毫克、维生素B6 2.1毫克、叶酸590微克、维生素B12 6.5微克、维生素D 2微克。
进一步,所述填充料为低能量甜味剂和/或速溶蛋白粉。
进一步,所述低能量甜味剂为山梨糖醇或赤鲜糖醇或木糖醇。
进一步,所述速溶蛋白粉包括大豆蛋白萃取物、分级除不溶物所得大豆脱脂粉、花生蛋白萃取物、分级除不溶物所得花生脱脂粉、食用油籽蛋白萃取物、分级除不溶物所得食用油籽脱脂粉和杂豆水萃取物经喷雾干燥得到的粉。
进一步,所述速溶蔬菜粉为番茄汁粉、黄瓜汁粉、沙棘叶汁粉、桑叶汁粉、白菜叶汁粉、茼蒿叶汁粉、苋菜叶汁粉、萝卜叶汁粉或萝卜汁粉中的至少一种。
上述一种富含心脑血管健康因子的固体饮料的制作方法,包括如下步骤:将所述配方原料混合均匀后,灭菌,最后采用干法造粒直接制成固体饮料或湿法造粒后干燥制成固体饮料。
进一步,所述灭菌采用6000W微波灭菌3min。
进一步,所述干燥温度为50℃。
本发明的配方依据如下:
维生素B3(尼克素):降低血液中甘油三脂及胆固醇,对血液循环有促进作用,具有辅助治疗高血压和糖尿病的作用。
叶酸:是制造红血球不可缺少的物质;对心脑血管病人而言,造血功能健全有利于心脑血管健康;日常饮食中叶酸缺乏或含量不足增加患心脑血管的风险,以及增加中风死亡率。
维生素B6:具有保护血管内皮细胞的作用(血管内皮细胞的损伤会引发动脉硬化症);此外,缺乏维生素B6增加血液中同半胱胺酸(homocysteine;发展高血压、动脉粥样硬化和糖尿病的独立危险因素)水平和炎症(形成血栓的启动因子)。
维生素B12:缺乏维生素B12增加血液中同半胱胺酸水平,从而增加患心脏病的风险。
维生素D:缺乏维生素D增加局部缺血性心脏病、心肌梗塞和早死性心脑血管疾病风险,此外适量补充维生素D能增加胰岛素灵敏性、降低抗胰岛素和降低空腹胰岛素水平。
甜菊甙:适量地摄入甜菊甙具有降血压、降血糖、防止动脉粥样硬化和修复胰岛细胞的作用。
精氨酸:在体内代谢能产生对血管有三大作用的一氧化氮,其三大作用为:1、扩张血管,2、防止低密度脂蛋白氧化和降低单核细胞黏附在血管壁上的程度,3、降低血小板的黏稠度。
茶多酚:具有降血脂、降血糖、抑制缺血性心脏病、抑制心肌梗塞、抑制或防止心肌炎的生理功能作用。
牛磺酸:具有降低血脂、抑制血小板凝集、保持人体正常血压和防止动脉硬化的功能,此外还具有保护心肌细胞和抗心律失常功能,特别是对降低血液中胆固醇含量有疗效,可用于治疗心力衰竭。
钾:缺乏钾可导致心跳不规律和加速、心电图异常、肌肉衰弱和烦躁,最后导致心跳停止(因为身体健康的人体能自动排出多余的钾,因此即使钾有轻微过量也不会导致不良反应)。
速溶姜粉:富含具有降血脂、抗血液凝集和抗炎症的姜黄素,其所含的姜辣素具有扩展末梢血管、降低血液低密度脂蛋白和减脂瘦身的功能。
速溶蔬菜粉:速溶蔬菜粉中富含B族维生素(见前面关于一些B族维生素的功能)和膳食多酚化合物(具有降低血液脂蛋白和减少体脂而缓解肥胖的功能),绿色速溶蔬菜粉中富含镁(缺镁增加患高血压、脑血管疾病、动脉裂口、血管内壁功能异常和炎症的风险);如果使用速溶十字花科蔬菜粉,则能提供丰富的硫甙,这种物质在体内缓慢释放硫化氢(H2S)而起到扩展血管等作用,能缓解或预防高血压等心脑血管疾病、以及具有降低血糖的作用),此外还含有芥子碱(具有保护心脑血管***和抗炎症功能)。
速溶杜仲叶汁粉:富含都桷子甙酸、鹅掌楸甙、松脂酚双葡萄糖甙和杜仲醇等生物活性物质,具有降压、降脂、降糖和抗炎症生理功能。
低聚肽:具有ACE抑制活性和抗氧化功能。
山梨糖醇:属于低能量甜味剂,具有预防肥胖的作用。
本发明配方中各成分虽然都有不同程度的降低血脂和血糖的作用,但每种组分侧重点和作用机制不同,配合使用后各组分起到协同增效和在日常饮食中尽可能地消除心脑血管疾病风险因子的作用,原料利用率高,对预防血脂和血糖升高及其辅助治疗的效果显著。本发明配方所用原料均为食品级,安全无毒副作用。
本发明的有益效果在于:
本发明饮料配方设计合理安全,各组分间相互协同作用,可以有效预防和辅助治疗心脑血管疾病,且该产品安全、有效性高、无毒副作用,是一种优质的预防和辅助治疗心脑血管疾病的日常饮料。
本发明饮料制备方法简单,适合规模化工业化生产。
具体实施方式
下面将结合本发明实施例,对本发明实施例中的技术方案进行清楚、完整的描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明所采用的一切配方原料均为市售常规购买,且都是食品级的。所采用原料中含有一种或者多种具有调节血脂或血糖的有效因子,且其含量在安全食用范围内。为了使所有有效因子都处于安全食用水平,而选用一种或多种食品级的填充料,即低能量甜味剂。按照科学的设定例,称取每一种配方原料后,经适当设备和方法混合均匀后,灭菌,最后通过干法造粒直接制成固体饮料或湿法造粒后干燥制成固体饮料(此步骤最好选择在无菌室中操作)。
本发明涉及一种富含心脑血管健康因子的固体饮料,该饮料包括如下配方原料:填充料40-70克、脱脂乳粉2-10克、低聚肽1-5克、精氨酸0.5-2克、速溶蔬菜粉0.5-4克、速溶杜仲叶汁粉0.5-4克、二氧化硅0.5-3克、茶多酚0.5-2克、速溶姜粉0.5-2克、甜菊甙0.1-0.2克、氯化钾1-2克、黄原胶0-1克、柠檬酸0-0.7克、羧甲基纤维素0-0.5克、牛磺酸0-0.2克、二氧化钛0-0.05克、尼克素32毫克、维生素B6 2.1毫克、叶酸590微克、维生素B12 6.5微克、维生素D 2微克。
本发明所涉及的填充料为低能量甜味剂和/或速溶蛋白粉,其中低能量甜味剂为山梨糖醇或赤鲜糖醇或木糖醇,速溶蛋白粉包括大豆蛋白萃取物、分级除不溶物所得大豆脱脂粉、花生蛋白萃取物、分级除不溶物所得花生脱脂粉、食用油籽蛋白萃取物、分级除不溶物所得食用油籽脱脂粉和杂豆水萃取物经喷雾干燥得到的粉;所涉及的速溶蔬菜粉为番茄汁粉、黄瓜汁粉、沙棘叶汁粉、桑叶汁粉、白菜叶汁粉、茼蒿叶汁粉、苋菜叶汁粉、萝卜叶汁粉或萝卜汁粉中的至少一种。
本发明配方中涉及的茶多酚原料可用脱咖啡因速溶茶粉全部或部分替代,所涉及的低聚肽原料可用食品级水溶性蛋白粉或蛋白胨全部或部分替代,所涉及的尼克素原料可用色氨酸代替。
本发明上述一种富含心脑血管健康因子的固体饮料制作方法,包括如下步骤:将上述配方原料混合均匀后灭菌,最后采用干法造粒直接制成固体饮料或湿法造粒后干燥制成固体饮料。灭菌采用6000W微波灭菌3min。干燥温度为50℃。
实施例1
一种富含心脑血管健康因子的固体饮料,其包括如下配方原料:山梨糖醇40.0克、脱脂乳粉2.0克、低聚肽1.0克、精氨酸0.5克、番茄汁粉0.5克、速溶杜仲叶汁粉0.5克、二氧化硅0.5克、茶多酚0.5克、速溶姜粉0.5克、甜菊甙0.1克、氯化钾1.0克、牛磺酸0.1克、尼克素32毫克、维生素B6 2.1毫克、叶酸590微克、维生素B12 6.5微克、维生素D 2微克。
一种富含心脑血管健康因子的固体饮料制作方法,包括如下步骤:将上述配方原料放入一锥形双螺旋破碎混合机中处理2小时混合均匀后,堆积1cm厚采用6000W微波灭菌3min,输入无菌室,采用干法造粒直接制成固体饮料后包装。
实施例2
一种富含心脑血管健康因子的固体饮料,其包括如下配方原料:赤鲜糖醇70.0克、脱脂乳粉10.0克、低聚肽5.0克、精氨酸2.0克、黄瓜汁粉4.0克、速溶杜仲叶汁粉4.0克、二氧化硅3.0克、茶多酚2.0克、速溶姜粉2.0克、甜菊甙0.2克、氯化钾2.0克、黄原胶1.0克、柠檬酸0.7克、羧甲基纤维素0.5克、牛磺酸0.2克、二氧化钛0.05克、尼克素32毫克、维生素B62.1毫克、叶酸590微克、维生素B12 6.5微克、维生素D 2微克。
一种富含心脑血管健康因子的固体饮料制作方法,包括如下步骤:将上述配方原料放入一锥形双螺旋破碎混合机中处理2小时混合均匀后,堆积1cm厚采用6000W微波灭菌3min,输入无菌室,采用干法造粒直接制成固体饮料后包装。
实施例3
一种富含心脑血管健康因子的固体饮料,其包括如下配方原料:速溶蛋白粉60.0克、脱脂乳粉6.0克、低聚肽3.0克、精氨酸1.0克、沙棘叶汁粉2.0克、桑叶汁1.0克、速溶杜仲叶汁粉2.0克、二氧化硅2.0克、茶多酚1.0克、速溶姜粉1.0克、甜菊甙0.2克、氯化钾1.5克、黄原胶0.5克、柠檬酸0.7克、羧甲基纤维素0.5克、牛磺酸0.2克、二氧化钛0.05克、尼克素32毫克、维生素B6 2.1毫克、叶酸590微克、维生素B12 6.5微克、维生素D 2微克。
一种富含心脑血管健康因子的固体饮料制作方法,包括如下步骤:将上述配方原料放入一锥形双螺旋破碎混合机中处理2小时混合均匀后,堆积1cm厚采用6000W微波灭菌3min,输入无菌室,采用湿法造粒后于50℃干燥制成固体饮料后包装。
实施例4
一种富含心脑血管健康因子的固体饮料,其包括如下配方原料:速溶蛋白粉70.0克、脱脂乳粉10.0克、低聚肽5.0克、精氨酸2.0克、沙棘叶汁粉2.0克、白菜叶汁粉2.0克、速溶杜仲叶汁粉4.0克、二氧化硅3.0克、茶多酚2.0克、速溶姜粉2.0克、甜菊甙0.2克、氯化钾2.0克、黄原胶1.0克、柠檬酸0.7克、羧甲基纤维素0.5克、牛磺酸0.2克、二氧化钛0.05克、尼克素32毫克、维生素B6 2.1毫克、叶酸590微克、维生素B12 6.5微克、维生素D 2微克。
一种富含心脑血管健康因子的固体饮料制作方法,包括如下步骤:将上述配方原料放入一锥形双螺旋破碎混合机中,并加入5%(w/w)桑叶汁处理2小时混合均匀后,堆积1cm厚采用6000W微波灭菌3min,输入无菌室,采用湿法造粒后于50℃干燥制成固体饮料后包装。
实施例5
经实际饮用试验证明本发明富含心脑血管健康因子的固体饮料对于心脑血管***的健康有显著的促进作用。本发明产品的实际饮用效果部分例子如下所示:
黄某某,男,1936年11月生,恩施市人,恩施农校退休,高级讲师,心血管轻微堵塞长达十多年之久。服本发明产品3年,头晕、头痛现象基本得到缓解,心脑血管堵塞明显改善。
田某某,男,1943年5月生,来凤县退休干部,长期在武汉生活,有轻微脑梗现象。服用本发明产品2年多,脑梗现象基本消除。
徐某某,女,1936年12月生,湖北省来凤县,农民,长期偏头痛。服用本发明产品4年,偏头痛大有改善。
罗某某,男。1947年10月生,湖北恩施市人,恩施农业局退休干部,脑动脉、颈动脉有轻微堵塞,脑梗现象。服用本发明产品3年,堵塞现象基本消失。
万某某,男,1944年生,来凤县烟草公司退休干部,常有心脏病供血不足现象。服用本发明产品3年,心脏病供血不足现象得到极大改善。
需要说明的是,在本文中,“包括”、“包含”或者其任何其他变体意在涵盖非排他性的包含,从而使得包括一系列要素的过程、方法、物品或者设备不仅包括那些要素,而且还包括没有明确列出的其他要素,或者是还包括为这种过程、方法、物品或者设备所固有的要素。
以上所述的仅是本发明的实施例,方案中公知常识在此未作过多描述,所属领域普通技术人员知晓申请日或者优先权日之前发明所属技术领域所有的普通技术知识,能够获知该领域中所有的现有技术,并且具有应用该日期之前常规实验手段的能力,所属领域普通技术人员可以在本申请给出的启示下,结合自身能力完善并实施本方案,一些典型的公知方法不应当成为所属领域普通技术人员实施本申请的障碍。本申请要求的保护范围应当以其权利要求的内容为准,说明书中的具体实施方式等记载可以用于解释权利要求的内容。
Claims (8)
1.一种富含心脑血管健康因子的固体饮料,其特征在于:所述饮料包括如下配方原料:填充料40-70克、脱脂乳粉2-10克、低聚肽1-5克、精氨酸0.5-2克、速溶蔬菜粉0.5-4克、速溶杜仲叶汁粉0.5-4克、二氧化硅0.5-3克、茶多酚0.5-2克、速溶姜粉0.5-2克、甜菊甙0.1-0.2克、氯化钾1-2克、黄原胶0-1克、柠檬酸0-0.7克、羧甲基纤维素0-0.5克、牛磺酸0-0.2克、二氧化钛0-0.05克、尼克素32毫克、维生素B6 2.1毫克、叶酸590微克、维生素B12 6.5微克、维生素D 2微克。
2.根据权利要求1所述的一种富含心脑血管健康因子的固体饮料,其特征在于:所述填充料为低能量甜味剂和/或速溶蛋白粉。
3.根据权利要求2所述的一种富含心脑血管健康因子的固体饮料,其特征在于:所述低能量甜味剂为山梨糖醇或赤鲜糖醇或木糖醇。
4.根据权利要求2所述的一种富含心脑血管健康因子的固体饮料,其特征在于:所述速溶蛋白粉包括大豆蛋白萃取物、分级除不溶物所得大豆脱脂粉、花生蛋白萃取物、分级除不溶物所得花生脱脂粉、食用油籽蛋白萃取物、分级除不溶物所得食用油籽脱脂粉和杂豆水萃取物经喷雾干燥得到的粉。
5.根据权利要求1所述的一种富含心脑血管健康因子的固体饮料,其特征在于:所述速溶蔬菜粉为番茄汁粉、黄瓜汁粉、沙棘叶汁粉、桑叶汁粉、白菜叶汁粉、茼蒿叶汁粉、苋菜叶汁粉、萝卜叶汁粉或萝卜汁粉中的至少一种。
6.根据权利要求1-5任一项所述的一种富含心脑血管健康因子的固体饮料的制作方法,其特征在于:包括如下步骤:将所述配方原料混合均匀后,灭菌,最后采用干法造粒直接制成固体饮料或湿法造粒后干燥制成固体饮料。
7.根据权利要求6所述的一种富含心脑血管健康因子的固体制作方法,其特征在于:所述灭菌采用6000W微波灭菌3min。
8.根据权利要求6所述的一种富含心脑血管健康因子的固体制作方法,其特征在于:所述干燥温度为50℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210919042.XA CN115251270A (zh) | 2022-08-02 | 2022-08-02 | 一种富含心脑血管健康因子的固体饮料及其制作方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210919042.XA CN115251270A (zh) | 2022-08-02 | 2022-08-02 | 一种富含心脑血管健康因子的固体饮料及其制作方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115251270A true CN115251270A (zh) | 2022-11-01 |
Family
ID=83747604
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210919042.XA Pending CN115251270A (zh) | 2022-08-02 | 2022-08-02 | 一种富含心脑血管健康因子的固体饮料及其制作方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115251270A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109123619A (zh) * | 2018-07-26 | 2019-01-04 | 刘建孚 | 一种供糖尿人群食用营养粉的配方及制备方法 |
CN109363045A (zh) * | 2018-12-26 | 2019-02-22 | 陕西天承生物科技股份有限公司 | 一种杜仲叶复方抗疲劳固体保健饮料及其制备方法 |
CN109938355A (zh) * | 2019-05-21 | 2019-06-28 | 国科润泽(山东)特医膳食科技有限公司 | 全科营养食品添加剂配方及其制备方法 |
CN110754655A (zh) * | 2019-11-01 | 2020-02-07 | 广州景腾医疗科技有限公司 | 一种低脂型全营养素配方及其制备方法 |
-
2022
- 2022-08-02 CN CN202210919042.XA patent/CN115251270A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109123619A (zh) * | 2018-07-26 | 2019-01-04 | 刘建孚 | 一种供糖尿人群食用营养粉的配方及制备方法 |
CN109363045A (zh) * | 2018-12-26 | 2019-02-22 | 陕西天承生物科技股份有限公司 | 一种杜仲叶复方抗疲劳固体保健饮料及其制备方法 |
CN109938355A (zh) * | 2019-05-21 | 2019-06-28 | 国科润泽(山东)特医膳食科技有限公司 | 全科营养食品添加剂配方及其制备方法 |
CN110754655A (zh) * | 2019-11-01 | 2020-02-07 | 广州景腾医疗科技有限公司 | 一种低脂型全营养素配方及其制备方法 |
Non-Patent Citations (2)
Title |
---|
冉懋雄 等: "《现代中药栽培养殖与加工手册》", 31 May 1999, 中国中医药出版社, pages: 1504 * |
马文领 等: "《心脑血管疾病预警与干预 CWPAS健康管理***概论》", 31 January 2014, 军事医学科学出版社, pages: 151 - 153 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190374569A1 (en) | Intact pea protein-based nutrient composition | |
KR101475138B1 (ko) | 신장 기능 강화 및 부종 개선에 효과적인 아르기닌 강화된 호박 등의 복합물을 유효성분으로 함유하는 조성물 | |
KR102295696B1 (ko) | 피로회복을 위한 경구용 수액분말 조성물 및 이의 제조방법 | |
CN101716007A (zh) | 一种肉桂生姜保健饮料及其制备方法 | |
EP2303297B1 (en) | Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism | |
CN105326053A (zh) | 含有左旋肉碱与壳寡糖的组合物及其制备方法和应用 | |
EP2303040A1 (en) | Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon | |
JP4119629B2 (ja) | 高血圧症予防・改善・治療剤 | |
CN102048225A (zh) | 一种具有改善生长发育功能的红枣保健饮料 | |
JP2005185188A (ja) | アセロラ処理物およびl−カルニチン含有組成物 | |
CN115251270A (zh) | 一种富含心脑血管健康因子的固体饮料及其制作方法 | |
CN103535625A (zh) | 一种调控血糖的食品及其制备方法 | |
KR101227922B1 (ko) | 파파야 퓌레 조제품 및 그 제조방법 | |
WO2016124080A1 (zh) | 20(R)-人参皂苷Rg3在制备预防或/和治疗肥胖症药物中的应用及药物 | |
RU2415611C1 (ru) | Биологически активная добавка к пище для профилактики заболеваний и оздоровления сердечно-сосудистой системы | |
KR20150083638A (ko) | 성장촉진 조성물 | |
KR101875896B1 (ko) | 말뼈와 산호를 주성분으로 포함하는 건강보조식품 및 그 제조방법 | |
CN112691150A (zh) | 一种组合物及其制备方法和应用 | |
CN111821388A (zh) | 一种红参组合物及其用途 | |
KR20150018167A (ko) | 천년초 발효물 함유 의약 조성물 | |
KR101658403B1 (ko) | 천연 당 시럽 및 그 제조 방법 | |
CN103518879A (zh) | 一种蜂蜜番茄萝卜茶及其制作方法 | |
KR102310233B1 (ko) | 혈류 개선용 건강기능식품 조성물 및 이의 제조 방법 | |
JPWO2009107878A1 (ja) | アデニンを高濃度に含有する野菜エキス、該野菜エキスを含むアデニン含有容器詰飲料、該野菜エキスを有効成分として含有してなる経口血圧降下剤組成物及びその製造方法 | |
CN115708533A (zh) | 一种预防和改善心脑血管疾病的功能茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |